![]() ![]() Hypersensitivity reactions have been reported with dolutegravir and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury.Do not use TIVICAY or TIVICAY PD in patients receiving dofetilide.Do not use TIVICAY or TIVICAY PD in patients with previous hypersensitivity reaction to dolutegravir.Presented at: Clinical Pharmacology of HIV and Hepatitis Therapy May 26-28, 2015 Washington, DC. Drug-drug interactions of ombitasvir/paritaprevir/r plus dasabuvir with dolutegravir or abacavir plus lamivudine. Princeton, NJ: Bristol-Myers Squibb Company 2017. Presented at: 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy May 26-28, 2015 Washington, DC. Evaluation of drug interactions between dolutegravir and daclatasvir in healthy subjects. ![]() Presented at: Conference on Retroviruses and Opportunistic Infections (CROI) February 23-26, 2015 Seattle, WA. Drug-drug interaction between HCV inhibitors grazoprevir/elbasvir with dolutegravir. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Rockstroh JK, Nelson M, Katlama C, et al. Titusville, NJ: Janssen Therapeutics 2017. Presented at:16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy May 26-28, 2015 Washington, DC. Drug interactions between anti-HCV antivirals ledipasvir/sofosbuvir and integrase strand transfer inhibitor-based regimens. 12 weeks of daclatasvir in combination with sofosbuvir for HIV-HCV coinfection (ALLY-2 study): efficacy and safety by HIV combination antiretroviral regimens. Luetkemeyer AF, McDonald C, Ramgopal M, et al. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Panel on Antiretroviral Guidelines for Adults and Adolescents. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |